A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan

This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Hepatocellular Adenocarcinoma Blood-Borne Infections Carcinoma Communicable Diseases DNA Virus Infections Digestive System Diseases Digestive System Neoplasms Fatty Liver Hepadnaviridae Infections Hepatitis Hepatitis B Hepatitis, Viral, Human Infections Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non-alcoholic Fatty Liver Disease Virus Diseases

Age range

27 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Darul Sehat Hospital

Karachi, Sindh, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged between 27 to 80 years.
Diagnosed with hepatocellular carcinoma (HCC) within the last three months.
Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy).
Able to provide informed consent.

Exclusion criteria

Elevated alpha-fetoprotein levels due to tumors other than HCC.
Presence of secondary liver metastases from other primary sites.
Any significant comorbid conditions that could interfere with study assessments.
Pregnancy or breastfeeding.

Treatment and study plan

Primary outcomes

Mean Alpha-Fetoprotein (AFP) Levels in HCC Patients

Time frame: Baseline measurement at time of diagnosis.

Secondary outcomes

Correlation Between AFP Levels and Tumor Size

Time frame: At baseline (upon diagnosis).

Sponsors and collaborators

Lead sponsor

Darul Sehat Hospital

Other

Registry information

Official study title

Clinical Correlation of Alpha-Fetoprotein in Hepatocellular Carcinoma: a Cross-Sectional Study from Southeast Asia

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Oct 8, 2024
Registry last updated: Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed